Dexrazoxane Intravenous and Insulin aspart, recombinant Subcutaneous
Determining the interaction of Dexrazoxane Intravenous and Insulin aspart, recombinant Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: dexrazoxane
Brand name: Totect, Zinecard
Synonyms: Dexrazoxane
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dexrazoxane Intravenous-Insulin degludec
- Dexrazoxane Intravenous-Insulin Degludec (U-100) Prefilled Pens
- Dexrazoxane Intravenous-Insulin Degludec (U-100) Vials
- Dexrazoxane Intravenous-Insulin Degludec (U-200) Prefilled Pens
- Dexrazoxane Intravenous-Insulin degludec and liraglutide
- Dexrazoxane Intravenous-Insulin degludec and liraglutide Subcutaneous
- Insulin aspart, recombinant Subcutaneous-Dextenza Insert
- Insulin aspart, recombinant Subcutaneous-Dextenza intraocular
- Insulin aspart, recombinant Subcutaneous-Dextran 40
- Insulin aspart, recombinant Subcutaneous-Dextran 70 6% in 5% Dextrose high molecular weight
- Insulin aspart, recombinant Subcutaneous-Dextran 75
- Insulin aspart, recombinant Subcutaneous-Dextran high molecular weight